FDA Offers New Tips for Proving Drug Effectiveness
Published Date: 6/24/2026
Notice
Summary
The FDA just released a new draft guide to help drug makers prove their medicines really work, using smarter and faster science. This update affects companies developing human drugs and biological products, aiming to save time and money by allowing strong evidence from just one good clinical study plus extra proof. Comments on this draft are open until September 22, 2026, so industry folks have a chance to weigh in before it becomes final.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
One Trial Plus Confirmatory Evidence
If you develop human drugs or biological products, FDA's revised draft guidance clarifies that sponsors can satisfy the substantial evidence of effectiveness standard by relying on one adequate and well-controlled clinical investigation plus confirmatory evidence. The guidance focuses on generating rigorous evidence in the most efficient manner and explains how the strength and type of confirmatory evidence can vary depending on the single trial.
Flexibility for Critical and Rare Diseases
The revised draft guidance retains discussion of regulatory flexibility in certain critical settings, including programs for diseases that lack effective treatments and rare diseases. FDA notes it may accept somewhat greater uncertainty about effectiveness in those settings when balanced against the risk of rejecting or delaying the marketing of an effective therapy.
1998 Guidance To Be Withdrawn
FDA plans to withdraw the 1998 guidance titled 'Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products' after finalizing this revised draft guidance, so the Agency's recommended approaches for meeting the substantial evidence standard will change. Sponsors should review the revised draft now and consider commenting before the September 22, 2026 deadline to influence the final recommendations.
No New FDA Paperwork Burden
FDA states the draft guidance contains no new collections of information and instead refers to previously approved collections under OMB control numbers 0910-0014, 0910-0001, and 0910-0338. That means the guidance itself does not impose new FDA paperwork or information-collection requirements on sponsors.
Public Comment Window Closes Sept 22, 2026
FDA is accepting electronic or written comments on this revised draft guidance through September 22, 2026 (Docket No. FDA-2019-D-4964). Industry stakeholders can submit comments at https://www.regulations.gov to have their views considered before FDA begins work on the final guidance.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15963, Medical Devices; Radiology Devices; Classification of the Fludeoxyglucose F18-Guided Radiation Therapy System
The Food and Drug Administration (FDA) is classifying the fludeoxyglucose F18-guided radiation therapy system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the fludeoxyglucose F18-guided radiation therapy system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-15964, Authorization of Emergency Use of an In Vitro Diagnostic Device in Response to an Outbreak of Mpox; Availability
The Food and Drug Administration (FDA or Agency) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in response to an outbreak of Mpox. FDA has issued an Authorization for an in vitro diagnostic device, Allplex HSV-1&2/VZV/ MPXV Assay, for the simultaneous qualitative detection and differentiation of viral nucleic acid from monkeypox virus (MPXV clade I/II and MPXV clade II)1, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella-zoster virus (VZV). The Authorization contains, among other things, conditions on the emergency use of the authorized product. The Authorization follows the August 9, 2022, determination by the Secretary of Health and Human Services (HHS) that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad, and that involves monkeypox virus. On the basis of such determination, the Secretary of HHS declared, on September 7, 2022, that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of infection with the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, pursuant to the FD&C Act, subject to terms of any authorization issued under that section. The Authorization, which includes an explanation of the reasons for issuance, is listed in this document, and can be accessed on FDA's website from the link indicated.
2026-15951, Evaluating the Safety of Antimicrobial New Animal Drugs With Regard to their Microbiological Effects on Bacteria of Human Health Concern; Guidance for Industry; Availability
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #152 entitled "Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern." This guidance document informs interested parties about FDA's current method for evaluating potential microbiological effects of antimicrobial new animal drugs on bacteria of human health concern as part of the new animal drug application process.
2026-15920, Micro-Tracers, Inc.; Response to Objections and Requests for a Public Hearing
The Food and Drug Administration (FDA or we) received objections and requests for a public hearing submitted by Buchanan Ingersoll & Rooney PC, on behalf of Micro-Tracers, Inc. (Micro-Tracers or objector), on the order granting a color additive petition (3C0323) requesting that we repeal specified regulations to no longer provide for the safe use of FD&C Red No. 3 in food (including dietary supplements) and ingested drugs. After reviewing the objections, we have concluded that the objections do not raise issues of material fact that justify a hearing. We are also providing notice that the administrative stay of the effective date for the repeal and delisting of the color additive regulations is now lifted.
Previous / Next Documents
Previous: 2026-12621, Expedited Investigational New Drug Pilot Program; Request for Information
The FDA wants to speed up how fast new drugs get tested on people by creating a special pilot program. This program will team up trusted research groups with drug makers to review early study plans faster, while keeping safety top priority. If you’re involved in drug research or healthcare, now’s your chance to share ideas before July 22, 2026!
Next: 2026-12623, Rockies Express Pipeline LLC, Cheyenne Connector, LLC, East Cheyenne Gas Storage, LLC; Notice of Revised Schedule for Environmental Review of the Critical Energy Reliability Link Project
The Rockies Express Pipeline project is taking a bit longer to review because they made some changes that affect new landowners. The environmental report will now come out on October 2, 2026, pushing the final decision deadline to December 31, 2026. This means more time for everyone to weigh in and make sure the project stays safe and sound.